Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

News Briefs: Biomet IPO; Hep C Screening Coverage; Valve Guidelines

This article was originally published in The Gray Sheet

Executive Summary

Biomet’s parent company filed an initial public offering registration statement for the firm March 7. CMS proposes national coverage for hepatitis C screening. ACC and AHA release new heart valve guidelines. More news.

You may also be interested in...



Allergan To Sell Lap-Band Franchise To Apollo For Up To $110 Million

The firm announced Oct. 29 an agreement with Apollo Endosurgery to sell its obesity intervention business, including the Lap-Band adjustable band.

Reimbursement Briefs: National Coverage Updates; MolDx Meeting Request; Sleep Study Questions

Hepatitis C virus screening national coverage supported in comments. Proposed decision memo delayed for percutaneous image-guided lumbar decompression for lumbar spinal stenosis national coverage determination. More reimbursement news.

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

Topics

Related Companies

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel